Clinical implications of chemotherapy-induced diarrhea in patients with cancer

Journal of Supportive Oncology

Volumn 3, Issue 3, 2005, Pages 227-232

  Goldberg Arnold, Renée J ^a,b   Gabrail, Nashat ^c   Raut, Monika ^d   Kim, Renée ^b   Sung, Jennifer C Y ^d   Zhou, Yonglong ^b  

^a LONG ISLAND UNIVERSITY   (United States)

^b Pharmacon International Inc   (United States)

^c Gabrail Cancer Center   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; TOPOTECAN; UFT;

ADULT; AGED; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; DEMOGRAPHY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNITED STATES;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 20744432616     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. National Cancer Institute. Common Terminology Criteria for Adverse Effects (CTCAE) v3.0. Available at: http://ctep.cancer.gov/reporting/ctc.html. Accessed March 15, 2004.
2. Wadler S, Benson AB 3rd, Engelking C, et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998;16:3169-3178.
3. Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22:2918-2926.
4. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801-3807.
5. Chu E, DeVita VT Jr. Principles of cancer management: chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:289-306.
6. Foote M. The importance of planned dose of chemotherapy on time: do we need to change our clinical practice? Oncologist 1998;3:365-368.
7. Hyrniuk WM. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol 1988:121-141.
8. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-977.
9. Landgren O, Algernon C, Axdorph U, et al. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 2003;88:438-444.
10. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracilin node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-906.
11. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
12. Arbuckle RB, Huber SL, Zacker C. The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 2000;5:250-259.
13. Stewart CF, Ratain MJ. Topoisomerase interactive agents. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:415-431.
14. Johnson SW, Stevenson JP, O'Dwyer PJ. Cisplatin and its analogues. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:376-388.
15. Hogan CM. The nurse's role in diarrhea management. Oncol Nurs Forum 1998;25:879-886.
16. Ippoliti C. Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients. Am J Health Syst Pharm 1998;55:1573-1580.
17. Cope DG. Management of chemotherapy-induced diarrhea and constipation. Nurs Clin North Am 2001;36:695-707.
18. Stern J, Ippoliti C. Management of acute cancer-treatment induced diarrhea. Sem Oncol Nurs 2003;19(suppl 3):11-16.